Novartis Healthcare Private Limited has announced the launch of the Sequadra indacaterol/glycopyrronium (110mcg/50mcg) DPI for the treatment of COPD in India. Novartis’s indacaterol/glycopyrronium DPI is marketed in Europe and Japan as Ultibro Breezhaler. Novartis filed an NDA for the inhaler with the FDA in late 2014.
Novartis India Country President Jawed Zia said, “NHPL is working hard to optimize this important treatment to Indian patients in a timely way. Once daily indacaterol/glycopyrronium combination reduces risk of annual rate of exacerbations by 31% compared to the current standard of care (twice-daily salmeterol + fluticasone combination) in patients with moderate-to-severe chronic obstructive pulmonary disease.”
Pulmonologist Deepak Talwar added, “It is great news that patients in India will now have access to this important long-acting bronchodilator combination therapy as the product offers better efficacy and superior patient outcomes in terms of compliance and convenience against all available standard of care medications in our country.”
